Abstract:Background: Emerging studies show that oxytocin administration improves social abilities in some patients with autism spectrum disorder (ASD). Besides, de novo mutations (DNMs) have been demonstrated to play strong functional effects in ASD. However, it remains unclear whether oxytocin-related genes (OTRGs) carry a significant DNM burden in ASD.Methods: In this study, we curated 7,767 coding DNMs from 6,790 ASD patients and 4,414 coding DNMs from 4,679 controls from publicly available whole-exome sequencing (WES) or whole-genome sequencing (WGS) studies and manually collected 963 OTRGs from four different resources. For the OTRGs, we compared the DNM rates between ASD patients and controls at different conditions, including genders (male and female), subcategories (autistic disorder, pervasive developmental disorder not otherwise specified, Asperger's syndrome), and non-verbal IQs (NVIQs, NVIQ ≤ 50, 50 < NVIQ ≤ 80, and NVIQ > 80).Outcomes: The DNM burden analysis showed that ASD patients didn't carry significantly more DNMs with different functional effects than the controls. This no significant result is still remained when taking gender, ASD subcategories and NVIQs, into consideration.Interpretation: Genetic DNM variants in OTRGs are not the major contributor for oxytocin's effect involving in ASD treatment, other genetic and environmental factor need to be further studied. The presence or absence of DNMs in OTRGs may not be the criteria for determining whether oxytocin should be used for ASD patients.Funding: National Natural Science Foundation of China, Young Elite Scientist Sponsorship Program by CAST (YESS), Key Research and Development Program of Guangdong Province, and Innovation-Driven Project of Central South University.Declaration of Interest: We declare no competing interests.

No Significant Association Between the De Novo Mutations in Oxytocin-Related Genes and Autism Spectrum Disorder